To the Editor: In the PREVENT IV study,1 edifoligide did not affect the rate of VGF, and on the basis of angiographic data the PREVENT IV investigators concluded that edifoligide did not have an appreciable effect on neointimal hyperplasia. We believe it may be premature to conclude that the lack of clinical benefit is due to a failure to inhibit neointimal proliferation and suggest 3 alternative explanations.
Lau GT, Kritharides L. Efficacy and Safety of Edifoligide. JAMA. 2006;295(13):1513–1515. doi:10.1001/jama.295.13.1513-b
Customize your JAMA Network experience by selecting one or more topics from the list below.